TGF-β1 attenuates spinal neuroinflammation and the excitatory amino acid system in rats with neuropathic pain

J Pain. 2013 Dec;14(12):1671-85. doi: 10.1016/j.jpain.2013.08.010.

Abstract

Previous studies have reported that the intrathecal (i.t.) administration of transforming growth factor β1 (TGF-β1) prevents and reverses neuropathic pain. However, only limited information is available regarding the possible role and effects of spinal TGF-β1 in neuropathic pain. We aimed to investigate the antinociceptive effects of exogenous TGF-β1 on chronic constriction injury (CCI)-induced neuropathic pain in rats. We demonstrated that sciatic nerve injury caused a downregulation of endogenous TGF-β1 levels on the ipsilateral side of the lumbar spinal dorsal gray matter, and that the i.t. administration of TGF-β1 (.01-10 ng) significantly attenuated CCI-induced thermal hyperalgesia in neuropathic rats. TGF-β1 significantly inhibited CCI-induced spinal neuroinflammation, microglial and astrocytic activation, and upregulation of tumor necrosis factor-α. Moreover, i.t. TGF-β1 significantly attenuated the CCI-induced downregulation of glutamate transporter 1, the glutamate aspartate transporter, and the excitatory amino acid carrier 1 on the ipsilateral side. Furthermore, i.t. TGF-β1 significantly decreased the concentrations of 2 excitatory amino acids, aspartate and glutamate, in the spinal dialysates in CCI rats. In summary, we conclude that the mechanisms of the antinociceptive effects of i.t. TGF-β1 in neuropathy may include attenuation of spinal neuroinflammation, attenuation, or upregulation of glutamate transporter downregulation, and a decrease of spinal extracellular excitatory amino acids.

Perspective: Clinically, medical treatment is usually initiated after the onset of intractable pain. Therefore, in the present study, i.t. TGF-β1 was designed to be administered 2 weeks after the establishment of CCI pain. Compared to the continuous TGF-β1 infusion mode, single-dose administration seems more convenient and practical to use.

Keywords: Transforming growth factor-β1; chronic constriction injury; excitatory amino acids; glutamate transporters; tumor necrosis factor-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / metabolism
  • Astrocytes / pathology
  • Down-Regulation / physiology
  • Excitatory Amino Acids / antagonists & inhibitors
  • Excitatory Amino Acids / metabolism*
  • Inflammation / metabolism
  • Inflammation / pathology
  • Inflammation / prevention & control
  • Injections, Spinal
  • Male
  • Microglia / metabolism
  • Microglia / pathology
  • Neuralgia / metabolism*
  • Neuralgia / pathology
  • Neuralgia / prevention & control*
  • Rats
  • Rats, Wistar
  • Sciatic Neuropathy / metabolism
  • Sciatic Neuropathy / pathology
  • Sciatic Neuropathy / prevention & control
  • Spinal Cord / drug effects
  • Spinal Cord / metabolism*
  • Spinal Cord / pathology
  • Transforming Growth Factor beta1 / administration & dosage*
  • Transforming Growth Factor beta1 / metabolism*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Excitatory Amino Acids
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha